Retroviral vectors are presently amongst the most widely used vectors in gene therapy
clinical trials to target pathologies of different origins, such as cancers, genetic diseases or …

The potential for gene therapy to cure a wide range of diseases has lead to high
expectations and a great increase in research efforts in this area. At present, viral vectors are …

For centuries mankind led a difficult battle against viruses, the smallest infectious agents at
the surface of the earth. Nowadays it is possible to use viruses for our benefit, both at a …

The majority of clinical trials for gene therapy currently employ retroviral-mediated gene
delivery. This is because the life cycle of the retrovirus is well understood and can be …

Retroviral vectors are still the vectors that are used in the majority of gene therapy trials for
treatment of acquired or inherited diseases. In this review, the present state‐of‐the‐art of the …

The broad application of retroviral vectors for gene delivery is still hampered by the difficulty
to reproducibly establish high vector producer cell lines generating sufficient amounts of …

For many applications, human clinical therapies using retroviral vectors still require many
technological improvements in key areas of vector design and production. These …

Efficient human gene therapy will rely on efficient gene delivery systems. To date,
recombinant, engineered retroviruses are the most widely used vectors for stable clinical …

Therapeutic gene delivery systems based on disabled murine retroviruses are now in
clinical trials for the treatment of disorders ranging from rare genetic diseases to cancer …

Since the first gene therapy clinical trial carried out by Rosenberg et al. in 1990 [1],
recombinant retroviral vectors are still the most popular gene delivery tools for gene therapy …